Adrenocortical carcinoma - null regimens
Revision as of 18:28, 25 March 2023 by Warner-admin (talk | contribs) (Text replacement - "|Years of enrollment" to "|Dates of enrollment")
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main adrenocortical carcinoma page for current regimens.
Recurrent, locally advanced, or metastatic disease
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Fassnacht et al. 2015 (GALACCTIC) | 2009-2011 | Phase 3 (C) | Linsitinib | Did not meet primary endpoint of OS Median OS: 356 vs 323 days |
No active antineoplastic treatment.
References
- GALACCTIC: Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. link to original article PubMed NCT00924989